Long-term Efficacy of Maintenance Bacillus Calmette-Guérin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up

European Urology

Volumn 56, Issue 2, 2009, Pages 260-265

  Järvinen, Riikka ^a   Kaasinen, Eero ^b   Sankila, Anna ^a   Rintala, Erkki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b HYVINKÄÄ HOSPITAL   (Finland)

Author keywords

Bacillus Calmette Guerin; Instillation therapy; Long term efficacy; Mitomycin C; Non muscle invasive bladder cancer; Recurrent

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CAPACITY; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 67649452008     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.04.009     Document Type: Article

References (21)

1. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
2. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
3. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guérin versus mitomycin-C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
4. Shelley M., Wilt T., Court J., Coles B., Kynaston H., and Mason M. Intravesical bacillus Calmette-Guérin in superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004) 485-490
5. Friedrich M.G., Pichlmeier U., Schwaibold H., Conrad S., and Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52 (2007) 1123-1130
6. Sylvester R., van der Meijden A., and Lamm D. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
7. Böhle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-686
8. Lamm D., Blumenstein B., Crissman J., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 163 (2000) 1124-1129
9. Gårdmark T., Jahnson S., Wahlquist R., Wijkström H., and Malmström P.U. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int 99 (2007) 817-820
10. Cookson M., Herr H., Zhang Z.F., Soloway S., Sogani P., and Fair W. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158 (1997) 62-67
11. Rintala E., Jauhiainen K., Alftan O., et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol 20 (1991) 19-25
12. Eksborg S., Nilsson S.O., and Edsmyr F. Intravesical instillation of Adriamycin. A model for standardization of the chemotherapy. Eur Urol 6 (1980) 218-220
13. Jauhiainen K., Kangas L., Nieminen A.L., Käpylä H., and Alfthan O. Optimizing mitomycin C activity during intravesical instillation. Urol Res 11 (1983) 59-62
14. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of statistics 16 (1988) 1141-1154
15. Fine J.P., and Gray R.J. A proportional hazards model for the subdistribution of a competing risk. JASA 94 (1999) 496-509
16. Malmström P.U., Wijkström H., Lundholm C., Wester K., Busch C., and Norlen B.J. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma: Swedish-Norwegian Bladder Cancer Study Group. J Urol 161 (1999) 1124-1127
17. Lamm D., Blumenstein B., Crawford D., et al. Randomized intergroup comparison of bacillus Calmette-Guérin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol 1 (1995) 119-126
18. Kaasinen E. What matters-early start or duration of chemotherapy instillation regimens or patient characteristics?. Eur Urol 53 (2008) 882-885
19. Sylvester R.J. Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment?. Eur Urol 52 (2007) 951-953
20. Au J.L., Badalament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93 (2001) 597-604
21. Raj G.V., Herr H., Serio A.M., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177 (2007) 1283-1286